YH-53   Click here for help

GtoPdb Ligand ID: 11646

Synonyms: compound 5h [PMID: 23994330] | compound 5h [PMID: 33510133] | GRL-2420 (compound 3 PMID: 34528437) | YH53
PDB Ligand
Compound class: Synthetic organic
Comment: YH-53 is a peptidomimetic, covalent inhibitor of coronavirus 3CL protease (3CLpro, Mpro), with reported inhibition of Mpro from SARS-CoV and SARS-CoV-2 [2-4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 170.52
Molecular weight 575.22
XLogP 3.35
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cccc2c1cc([nH]2)C(=O)N[C@H](C(=O)N[C@H](C(=O)c1nc2c(s1)cccc2)C[C@@H]1CCNC1=O)CC(C)C
Isomeric SMILES s1c(nc2c1cccc2)C(=O)[C@H](C[C@H]1C(=O)NCC1)NC(=O)[C@H](CC(C)C)NC(=O)c1[nH]c2cccc(c2c1)OC
InChI InChI=1S/C30H33N5O5S/c1-16(2)13-22(34-29(39)23-15-18-19(32-23)8-6-9-24(18)40-3)28(38)33-21(14-17-11-12-31-27(17)37)26(36)30-35-20-7-4-5-10-25(20)41-30/h4-10,15-17,21-22,32H,11-14H2,1-3H3,(H,31,37)(H,33,38)(H,34,39)/t17-,21-,22-/m0/s1
InChI Key JBLLRCOZJMVOAE-HSQYWUDLSA-N
References
1. Ghosh AK, Raghavaiah J, Shahabi D, Yadav M, Anson BJ, Lendy EK, Hattori SI, Higashi-Kuwata N, Mitsuya H, Mesecar AD. (2021)
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
J Med Chem, 64 (19): 14702-14714. [PMID:34528437]
2. Hattori SI, Higashi-Kuwata N, Hayashi H, Allu SR, Raghavaiah J, Bulut H, Das D, Anson BJ, Lendy EK, Takamatsu Y et al.. (2021)
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Nat Commun, 12 (1): 668. [PMID:33510133]
3. Konno S, Kobayashi K, Senda M, Funai Y, Seki Y, Tamai I, Schäkel L, Sakata K, Pillaiyar T, Taguchi A et al.. (2022)
3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
J Med Chem, 65 (4): 2926-2939. [PMID:34313428]
4. Thanigaimalai P, Konno S, Yamamoto T, Koiwai Y, Taguchi A, Takayama K, Yakushiji F, Akaji K, Chen SE, Naser-Tavakolian A et al.. (2013)
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.
Eur J Med Chem, 68: 372-84. [PMID:23994330]